Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three sympathomimetic medications that act on adrenergic receptors. Each component has distinct pharmacological properties: - **Dopamine**: Stimulates β1-adrenergic receptors to increase cardiac contractility and output. At higher doses, it also stimulates α-receptors causing vasoconstriction. - **Epinephrine**: A nonselective adrenergic agonist that stimulates both β1 and β2 receptors, causing bronchodilation and cardiac stimulation. Also acts on α-receptors to cause vasoconstriction. - **Norepinephrine**: Primarily stimulates β1-receptors in the heart and has strong α-receptor activity, causing vasoconstriction and increasing blood pressure. While these medications can sometimes be used together in critical care settings, they are typically administered separately based on specific clinical needs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dopamine + epinephrine + norepinephrine.